These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28775248)

  • 1. Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection.
    Ban TH; Yu JH; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Ann Transplant; 2017 Aug; 22():468-474. PubMed ID: 28775248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
    Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
    Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
    Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients.
    An GH; Yun J; Hong YA; Khvan M; Chung BH; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
    J Immunol Res; 2014; 2014():828732. PubMed ID: 24741626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.
    Mulley WR; Huang LL; Ramessur Chandran S; Longano A; Amos LAR; Polkinghorne KR; Nikolic-Paterson DJ; Kanellis J
    Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.
    Piñeiro GJ; De Sousa-Amorim E; Solé M; Ríos J; Lozano M; Cofán F; Ventura-Aguiar P; Cucchiari D; Revuelta I; Cid J; Palou E; Campistol JM; Oppenheimer F; Rovira J; Diekmann F
    BMC Nephrol; 2018 Oct; 19(1):261. PubMed ID: 30309322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients: Single-Center Experience.
    Nair P; Gheith O; Al-Otaibi T; Mostafa M; Rida S; Sobhy I; Halim MA; Mahmoud T; Abdul-Hameed M; Maher A; Emam M
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):113-119. PubMed ID: 30777534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
    Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
    Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation.
    Yamanashi K; Chen-Yoshikawa TF; Hamaji M; Yurugi K; Tanaka S; Yutaka Y; Yamada Y; Nakajima D; Ohsumi A; Date H
    Gen Thorac Cardiovasc Surg; 2020 Feb; 68(2):142-149. PubMed ID: 31435872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation.
    Cihan Y; Kanzelmeyer N; Drube J; Kreuzer M; Lerch C; Hennies I; Froede K; Verboom M; Ahlenstiel-Grunow T; Pape L
    Pediatr Nephrol; 2017 Nov; 32(11):2133-2142. PubMed ID: 28717935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Bortezomib as an Adjunctive Therapy for Refractory Chronic Active Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
    Larpparisuth N; Skulratanasak P; Premasathian N; Vongwiwatana A
    Transplant Proc; 2019 Dec; 51(10):3293-3296. PubMed ID: 31732214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
    Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
    Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
    Sautenet B; Blancho G; Büchler M; Morelon E; Toupance O; Barrou B; Ducloux D; Chatelet V; Moulin B; Freguin C; Hazzan M; Lang P; Legendre C; Merville P; Mourad G; Mousson C; Pouteil-Noble C; Purgus R; Rerolle JP; Sayegh J; Westeel PF; Zaoui P; Boivin H; Le Gouge A; Lebranchu Y
    Transplantation; 2016 Feb; 100(2):391-9. PubMed ID: 26555944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Antibody-mediated Rejection 1 Week After Lung Transplantation Successfully Treated With Eculizumab, Intravenous Immunoglobulins, and Rituximab.
    Muller YD; Aubert JD; Vionnet J; Rotman S; Sadallah S; Aubert V; Pascual M
    Transplantation; 2018 Jun; 102(6):e301-e303. PubMed ID: 29521880
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of rituximab therapy for treatment of acute humoral rejection.
    Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
    Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.